Cogent Biosciences (COGT) Non-Current Assets (2017 - 2026)

Cogent Biosciences (COGT) has reported Non-Current Assets for 10 consecutive years, with $25.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Non-Current Assets fell 18.47% year-over-year to $25.2 million; the TTM figure through Mar 2026 stood at $111.0 million (down 32.67% YoY), while the FY2025 annual figure was $27.3 million, down 13.28% from the prior year.
• Non-Current Assets eased to $25.2 million in Q1 2026 per COGT's latest filing, from $27.3 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $69.5 million in Q3 2023 and bottomed at $12.1 million in Q1 2022.
• Historically, Non-Current Assets has averaged $37.4 million across 5 years, with a median of $35.1 million in 2022.
• Annual changes were most pronounced in 2022 — Non-Current Assets jumped 393.68% — and 2025, when it tumbled 50.29%.
• Cogent Biosciences' Non-Current Assets stood at $35.8 million in 2022, then advanced by 19.03% to $42.7 million in 2023, then slipped by 26.34% to $31.4 million in 2024, then retreated by 13.28% to $27.3 million in 2025, then decreased by 7.52% to $25.2 million in 2026.
• Business Quant data shows COGT's Non-Current Assets at $25.2 million in Q1 2026, $27.3 million in Q4 2025, and $28.7 million in Q3 2025.